Despite many years of research, no biomarkers for stroke are available to use in clinical
practice. Progress in high-throughput technologies has provided new opportunities to …

The global nephrology community recognises the need for a cohesive plan to address the
problem of chronic kidney disease (CKD). In July, 2016, the International Society of …

The use of multiple omics techniques (ie, genomics, transcriptomics, proteomics, and
metabolomics) is becoming increasingly popular in all facets of life science. Omics …

The accurate definition and staging of chronic kidney disease (CKD) is one of the major
achievements of modern nephrology. Intensive research is now being undertaken to unravel …

The drug discovery process starts with identification of a disease-modifying target. This
critical step traditionally begins with manual investigation of scientific literature and …

Kinetic models of metabolism at a genome scale that faithfully recapitulate the effect of
multiple genetic interventions would be transformative in our ability to reliably design novel …

Drug discovery from natural sources is going through a renaissance, having spent many
decades in the shadow of synthetic molecule drug discovery, despite the fact that natural …

Chronic kidney disease (CKD) refers to a range of various pathophysiological processes
correlated with abnormal renal function and a progressive loss in GFR. Just as dysbiosis …

Ischemic stroke (IS) is a multifactorial and heterogeneous neurological disorder with high
rate of death and long-term impairment. Despite years of studies, there are still no stroke …

Alzheimer's Disease (AD) is a neurodegenerative disease that affects cognition and is the
most common cause of dementia in the elderly. As the number of elderly individuals …